A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions

Sponsor
Boryung Pharmaceutical Co., Ltd
Study ID
NCT06890299
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • BR3006 — DRUG
    One tablet administered alone
  • BR3006A — DRUG
    One tablet administered alone
  • BR3006B — DRUG
    One tablet administered alone
  • BR3006C — DRUG
    One tablet administered alone

Study Details

The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions

Key Dates

First listed
Mar 24, 2025
Start date
Dec 5, 2024
Status verified
Mar 2025
Primary completion
Jan 12, 2025
Completion
Jan 12, 2025

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: BR3006
  • Active Comparator: BR3006A+BR3006B+BR3006C

Primary Outcome Measure

AUCt [ Time Frame: 0-48 hours after administration ]

Related Studies